NO316256B1 - Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose - Google Patents
Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose Download PDFInfo
- Publication number
- NO316256B1 NO316256B1 NO19981856A NO981856A NO316256B1 NO 316256 B1 NO316256 B1 NO 316256B1 NO 19981856 A NO19981856 A NO 19981856A NO 981856 A NO981856 A NO 981856A NO 316256 B1 NO316256 B1 NO 316256B1
- Authority
- NO
- Norway
- Prior art keywords
- naphth
- ylethyl
- pharmaceutically acceptable
- treatment
- trifluoromethylphenyl
- Prior art date
Links
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000002253 acid Substances 0.000 claims abstract description 13
- 150000007513 acids Chemical class 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims 2
- 201000008266 amyotrophic lateral sclerosis type 2 Diseases 0.000 claims 1
- 201000008715 amyotrophic lateral sclerosis type 8 Diseases 0.000 claims 1
- 208000032799 juvenile amyotrophic lateral sclerosis type 2 Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9512635A FR2740343B1 (fr) | 1995-10-26 | 1995-10-26 | Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique |
| FR9607336 | 1996-06-13 | ||
| PCT/FR1996/001674 WO1997015304A1 (fr) | 1995-10-26 | 1996-10-25 | Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981856D0 NO981856D0 (no) | 1998-04-24 |
| NO981856L NO981856L (no) | 1998-06-11 |
| NO316256B1 true NO316256B1 (no) | 2004-01-05 |
Family
ID=26232287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981856A NO316256B1 (no) | 1995-10-26 | 1998-04-24 | Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6043251A (sk) |
| EP (1) | EP0866704B1 (sk) |
| JP (1) | JP3468526B2 (sk) |
| KR (1) | KR100472793B1 (sk) |
| CN (1) | CN1104241C (sk) |
| AT (1) | ATE200423T1 (sk) |
| AU (1) | AU719342B2 (sk) |
| BR (1) | BR9611124A (sk) |
| CA (1) | CA2235747C (sk) |
| CY (1) | CY2279B1 (sk) |
| CZ (1) | CZ293360B6 (sk) |
| DE (1) | DE69612510T2 (sk) |
| DK (1) | DK0866704T3 (sk) |
| EE (1) | EE04177B1 (sk) |
| ES (1) | ES2159362T3 (sk) |
| GR (1) | GR3036027T3 (sk) |
| HK (1) | HK1016904A1 (sk) |
| HU (1) | HU222039B1 (sk) |
| IL (1) | IL124091A (sk) |
| IS (1) | IS1961B (sk) |
| NO (1) | NO316256B1 (sk) |
| NZ (1) | NZ320355A (sk) |
| PT (1) | PT866704E (sk) |
| SI (1) | SI0866704T1 (sk) |
| SK (1) | SK284099B6 (sk) |
| TR (1) | TR199800717T2 (sk) |
| UA (1) | UA57004C2 (sk) |
| WO (1) | WO1997015304A1 (sk) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2782008B1 (fr) * | 1998-08-07 | 2003-04-25 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique |
| EP2305252A1 (en) * | 2001-12-11 | 2011-04-06 | University Of Virginia Patent Foundation | Use of pramipexole to treat amyotrophic lateral sclerosis |
| US20060281797A1 (en) * | 2001-12-11 | 2006-12-14 | University Of Virginia Patent Foundation | Neurorestoration with R(+) Pramipexole |
| CN102727501A (zh) * | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| CA2619217A1 (en) * | 2005-08-15 | 2007-02-22 | University Of Virginia Patent Foundation | Neurorestoration with r(+) pramipexole |
| US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| CA2652251A1 (en) | 2006-05-16 | 2007-11-29 | Knopp Neurosciences, Inc. | Compositions of r(+) and s(-) pramipexole and methods for using the same |
| US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| WO2008113056A2 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| US20110190356A1 (en) * | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| CN105764507B (zh) | 2013-07-12 | 2019-07-19 | 诺普生物科学有限责任公司 | 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平 |
| ES2871556T3 (es) | 2013-08-13 | 2021-10-29 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de la urticaria crónica |
| ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2662355B1 (fr) * | 1990-05-22 | 1994-11-10 | Sanofi Sa | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
| FR2672213B1 (fr) * | 1991-02-05 | 1995-03-10 | Sanofi Sa | Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres. |
| FR2672731A1 (fr) * | 1991-02-07 | 1992-08-14 | France Telecom | Procede d'oxydation localisee enterree d'un substrat de silicium et circuit integre correspondant. |
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
-
1996
- 1996-10-25 UA UA98042073A patent/UA57004C2/uk unknown
- 1996-10-25 PT PT96934975T patent/PT866704E/pt unknown
- 1996-10-25 WO PCT/FR1996/001674 patent/WO1997015304A1/fr active IP Right Grant
- 1996-10-25 NZ NZ320355A patent/NZ320355A/xx unknown
- 1996-10-25 CA CA002235747A patent/CA2235747C/en not_active Expired - Fee Related
- 1996-10-25 TR TR1998/00717T patent/TR199800717T2/xx unknown
- 1996-10-25 HU HU9802945A patent/HU222039B1/hu not_active IP Right Cessation
- 1996-10-25 CN CN96198508A patent/CN1104241C/zh not_active Expired - Fee Related
- 1996-10-25 BR BR9611124A patent/BR9611124A/pt not_active Application Discontinuation
- 1996-10-25 EP EP96934975A patent/EP0866704B1/fr not_active Expired - Lifetime
- 1996-10-25 EE EE9800132A patent/EE04177B1/xx not_active IP Right Cessation
- 1996-10-25 IL IL12409196A patent/IL124091A/xx not_active IP Right Cessation
- 1996-10-25 SI SI9630299T patent/SI0866704T1/xx unknown
- 1996-10-25 DE DE69612510T patent/DE69612510T2/de not_active Expired - Fee Related
- 1996-10-25 JP JP51637097A patent/JP3468526B2/ja not_active Expired - Fee Related
- 1996-10-25 SK SK526-98A patent/SK284099B6/sk unknown
- 1996-10-25 AT AT96934975T patent/ATE200423T1/de not_active IP Right Cessation
- 1996-10-25 KR KR10-1998-0702997A patent/KR100472793B1/ko not_active IP Right Cessation
- 1996-10-25 ES ES96934975T patent/ES2159362T3/es not_active Expired - Lifetime
- 1996-10-25 CZ CZ19981296A patent/CZ293360B6/cs not_active IP Right Cessation
- 1996-10-25 DK DK96934975T patent/DK0866704T3/da active
- 1996-10-25 AU AU73084/96A patent/AU719342B2/en not_active Ceased
- 1996-10-25 US US09/051,740 patent/US6043251A/en not_active Expired - Fee Related
-
1998
- 1998-04-21 IS IS4722A patent/IS1961B/is unknown
- 1998-04-24 NO NO19981856A patent/NO316256B1/no unknown
-
1999
- 1999-05-24 HK HK99102262A patent/HK1016904A1/xx not_active IP Right Cessation
-
2001
- 2001-06-13 GR GR20010400880T patent/GR3036027T3/el not_active IP Right Cessation
-
2002
- 2002-05-15 CY CY0200033A patent/CY2279B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO316256B1 (no) | Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose | |
| Frank et al. | Lamictal (lamotrigine) monotherapy for typical absence seizures in children | |
| JP2010511616A (ja) | 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法 | |
| DE60009697T2 (de) | Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie | |
| CN110691593B (zh) | 脊髓小脑变性症预防或治疗剂 | |
| US20060241133A1 (en) | Electrically variable pneumatic structural element | |
| EP1420782B1 (en) | Use of nefiracetam for treating post-stroke neurodegeneration | |
| TW202038955A (zh) | 用於治療多巴胺性cns病症之ly3154207劑量療法 | |
| Loose et al. | Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold | |
| TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
| Van Der Meyden et al. | Acute oral loading of carbamazepine‐CR and phenytoin in a double‐blind randomized study of patients at risk of seizures | |
| US20070202503A1 (en) | Pharmaceutical Composition Of (+)-Erythro-Mefloquine And Its Use | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
| MXPA98003271A (en) | Use of 1- (2-naft-2-iletil) -4- (3-trifluorometilfenil) -1, 2, 3, 6-tetrahydropiridine for the preparation of drugs for the treatment of lateral sclerosis amiotrof | |
| WO2023227881A1 (en) | Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction | |
| EP0626849A1 (en) | Brofaromine as an agent for treating post-traumatic stress | |
| CN114259486A (zh) | 木犀草素及其药物组合物的应用 | |
| WO2011110608A1 (en) | Treatment of dementia of alzheimer's type with masitinib | |
| WO2004032932A1 (de) | Verwendung von 5-ht2-rezeptorantagonisten zur behandlung von schlafstörungen |